Vimarsana
Biggest News Aggregation in the World

Page 27 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA Versus IMBRUVICA in Late-Breaking Oral Session at ASH 2022 - Vimarsana News

BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA Versus IMBRUVICA in Late-Breaking Oral Session at ASH 2022

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented

BeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL) - Vimarsana News

BeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)

BRUKINSA is the only Bruton's Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA (ibrutinib) in relapsed/refractory CLL. BRUKINSA also showed superiority to chemoimmunotherapy

BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care - Vimarsana News

BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the launch of a new program, Talk About It: Cancer and Mental Health, designed to elevate the important

BeiGene Announces Brazil Approvals for BRUKINSA As a Treatment for Rare Blood Cancers - Vimarsana News

BeiGene Announces Brazil Approvals for BRUKINSA As a Treatment for Rare Blood Cancers

BRUKINSA now approved in Brazil for three indications BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology, today announced BRUKINSA (zanubrutinib) has been approved in Brazil

BeiGene, Ltd.: BeiGene Reports Third Quarter 2022 Financial Results - Vimarsana News

BeiGene, Ltd.: BeiGene Reports Third Quarter 2022 Financial Results

Recorded product revenue of $349.5 million for the third quarter, representing an 82% increase from $192.5 million in the prior-year period BRUKINSA product revenue totaled $155.5 million, increasing